• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

CoLucid Pharmaceuticals - Articles and news items

Eli Lilly to aquire pain biotech CoLucid for $960 million

Industry news / 19 January 2017 / Niamh Marriott, Digital Editor

This transaction will be acting to enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch…

CoLucid Pharmaceuticals announces initiation of first Phase 3 pivotal trial of lasmiditan in migraine

Industry news / 30 April 2015 / Victoria White

CoLucid Pharmaceuticals has announced that the first patient has been randomised in its SAMURAI study, the Company’s Phase 3 pivotal trial of lasmiditan…